Nel, A.Van Niekerk, N.Kapiga, S.Bekker, S.-G.Gama, C.Kamali, A.Kotze, P.Louw, CherylMAbude, Z.Miti, N.Kusemererwa, S.Tempelman, H.Carstens, H.Devlin, B.Isaacs, M.Malherbe, M.Mans, W.Nuttall, J.Russell, M.Ntshele, S.Smit, M.Solai, L.Spence, P.Steyler, J.Windle, K.Borremans, M.Resseler, S.Van Roey, J.Parys, W.Vangeneugden, T.Van Baelen, B.Rosenberg, Z.2017-01-232016-12-01Nel, A, Van Niekerk, S, Kapiga, S, Bekker, L-G, Gama, C, Gill, K, Kamali, A, Kotze, P, Louw, C, Mabude, Z, Miti, N, Kusemererwa, S, Tempelman, H, Carstens, H, Devlin, B, Isaacs, M, Malherbe, M, Mans, W, Nuttall, J, Russell, M, Ntshele, S, Smit, M, Solai, L, Spence, P. Steytler, J, Windle, K, Borremans, M, Resseler, S. Van Roey, J. Parys, W. Vangeneugden, T, Van Baelen, B & Rosenberg, Z 2016, ‘Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women', New England Journal of Medicine, vol. 375, no. 22, pp. 2133-2143.0028-4793 (print)1533-4406 (online)10.1056/NEJMoa1602046 untranslatedhttp://hdl.handle.net/2263/58598BACKGROUND The incidence of human immunodeficiency virus (HIV) infection remains high among women in sub-Saharan Africa. We evaluated the safety and efficacy of extended use of a vaginal ring containing dapivirine for the prevention of HIV infection in 1959 healthy, sexually active women, 18 to 45 years of age, from seven communities in South Africa and Uganda. METHODS In this randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned participants in a 2:1 ratio to receive vaginal rings containing either 25 mg of dapivirine or placebo. Participants inserted the rings themselves every 4 weeks for up to 24 months. The primary efficacy end point was the rate of HIV type 1 (HIV-1) seroconversion. RESULTS A total of 77 participants in the dapivirine group underwent HIV-1 seroconversion during 1888 person-years of follow-up (4.1 seroconversions per 100 person-years), as compared with 56 in the placebo group who underwent HIV-1 seroconversion during 917 person-years of follow-up (6.1 seroconversions per 100 person-years). The incidence of HIV-1 infection was 31% lower in the dapivirine group than in the placebo group (hazard ratio, 0.69; 95% confidence interval [CI], 0.49 to 0.99; P = 0.04). There was no significant difference in efficacy of the dapivirine ring among women older than 21 years of age (hazard ratio for infection, 0.63; 95% CI, 0.41 to 0.97) and those 21 years of age or younger (hazard ratio, 0.85; 95% CI, 0.45 to 1.60; P = 0.43 for treatment-by-age interaction). Among participants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations were detected in 14 of 77 participants in the dapivirine group (18.2%) and in 9 of 56 (16.1%) in the placebo group. Serious adverse events occurred more often in the dapivirine group (in 38 participants [2.9%]) than in the placebo group (in 6 [0.9%]). However, no clear pattern was identified. CONCLUSIONS Among women in sub-Saharan Africa, the dapivirine ring was not associated with any safety concerns and was associated with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo.en© 2016 Massachusetts Medical SocietyWomenDapivirine ringTreatmentHIV-1 infectionHuman immunodeficiency virus (HIV)Vaginal ringHealth sciences articles SDG-03SDG-03: Good health and well-beingArticle